Company Encyclopedia
View More
name
SIMCERE PHARMA
02096.HK
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN simnotrelvir tablets and ritonavir tablets. The company also offers promotional services for pharmaceutical products.
1.477 T
02096.HKMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking4/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.45%B
    • Profit Margin12.39%B
    • Gross Margin80.72%A
  • Growth ScoreB
    • Revenue YoY12.27%B
    • Net Profit YoY179.97%A
    • Total Assets YoY9.62%B
    • Net Assets YoY6.66%B
  • Cash ScoreB
    • Cash Flow Margin807.41%B
    • OCF YoY12.27%B
  • Operating ScoreB
    • Turnover0.58B
  • Debt ScoreC
    • Gearing Ratio42.61%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Certain Orinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 9-DEC-2025.

    Certain Orinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-Up Agreement Ending on 9-DEC-2025. These Orinary Shares will be under lockup for 90 days starting from 10-SEP-2025 to 9-DEC-2025. Details: Pursuant to the Placing and Subscription Agreement, the Vendor undertakes to the Placing Agent that except for the sale of the Sale Shares pursuant to the Placing and Subscription Agreement for a period of 90 days from the Placing Closing Date.

    marketscreener·
    HK
    02096
    -0.80%
    marketscreener·
    HK
    02096
    -0.80%

    Simcere’s ENZESHU® and ENDOSTAR® Included in China’s National Reimbursement Drug List

    Simcere Pharmaceutical Group Limited announced that its drugs ENZESHU® and ENDOSTAR® have been included in China's National Reimbursement Drug List. ENZESHU® is approved for certain cancers, while ENDOSTAR® treats advanced non-small cell lung cancer. This inclusion is expected to improve market positioning and patient access. The latest analyst rating for Simcere's stock (HK:2096) is a Buy with a HK$16.30 price target.

    Tip Ranks·
    HK
    02096
    -0.80%
    Tip Ranks·
    HK
    02096
    -0.80%

    Simcere climbs on license deal with Vigonvita

    ** Simcere Pharmaceutical Group climbs 3.7% to HK$13.59; set for biggest one-day pct gain since November 13** Stock set to snap two straight sessions of fall** Generic drug producer obtains exclusive license rights to Vigonvita Life Science's Deuterated Remdesivir Hydrobromide in the Greater China region** Drug used to treat respiratory syncytial virus, human metapneumovirus (HMPV) infection** Co says collaboration will strengthen group's product deployment in anti-infection area** Vigonvita's stock slips 2.5% to HK$74.1** YTD, Simcere shares up 90%; Vigonvita's stock surges 236.8% since listing in Hong Kong on November 6

    Reuters·
    HK
    02096
    -0.80%
    Reuters·
    HK
    02096
    -0.80%

    Vigonvita Life Sciences Signs License Agreement With Simcere Pharmaceutical for VV116 New Indications

    Vigonvita Life Sciences Co. Ltd. has signed a license agreement with Simcere Pharmaceutical Group Limited. Simcere will receive exclusive rights for Vigonvita's drug candidate, deuremidevir hydrobromide (VV116), in Greater China for new indications, specifically for treating infections caused by RSV and HMPV.

    Reuters·
    HK
    02096
    -0.80%
    Reuters·
    HK
    02096
    -0.80%

    Simcere Pharma Grants 15.4 million RSUs Under Incentive Scheme; Shares Slip 4%

    Simcere Pharma Grants 15.4 million RSUs Under Incentive Scheme; Shares Slip 4%

    marketscreener·
    HK
    02096
    -0.80%
    marketscreener·
    HK
    02096
    -0.80%
    © 2025 Longbridge｜Disclaimer